Get the Daily Brief
Latest Biotech News
GaAs hybrid-pixel detector enhances 100 keV cryo-EM imaging
Researchers unveiled a gallium arsenide (GaAs) hybrid‑pixel counting detector optimized for 100 keV electron beams that boosts cryo‑EM performance at lower accelerating voltages. The hardware...
Ferroptosis nanotherapy reprograms colorectal cancer fibroblasts
A study led by Wang and colleagues reports a ferroptosis-based nanotherapy that selectively targets colorectal cancer‑associated fibroblasts (CAFs), reversing their tumor-supportive phenotype and...
Oral foam delivers gene therapy—targets constrictive esophageal carcinoma
Researchers Stephan, Cummings and Fitzgerald introduced a drinkable gene‑therapy foam formulation designed to coat the esophageal lumen and deliver genetic payloads to constrictive esophageal...
Extracellular vesicles repurposed for precise, nonviral delivery
A review/innovation piece outlines progress in engineering extracellular vesicles (EVs) as nonviral vectors for gene and protein delivery, arguing EVs can reduce immunogenicity and improve...
GLP‑1 triggers KATP in coronary pericytes—mechanism for cardioprotection
A Nature Communications study shows glucagon‑like peptide‑1 (GLP‑1) activates ATP‑sensitive potassium (KATP) channels in coronary pericytes, producing vasodilatory and protective effects on...
BDNF‑derived dodecapeptide antagonizes TLR4—potential ALI therapy
A Nature Communications paper reports that brain‑derived neurotrophic factor (BDNF) and a synthetic dodecapeptide derived from it antagonize Toll‑like receptor 4 (TLR4), reducing innate immune...
Exact Sciences Revenue Rises 23%—Shareholders Set to Vote on $23B Abbott Deal
Exact Sciences reported 23% year-over-year revenue growth for Q4 2025 and confirmed a special shareholder vote on its proposed $23 billion acquisition by Abbott. The company posted $878.4 million...
BridgeBio’s Infigratinib Matches Voxzogo on Height: Oral FGFR3 Option Emerges
BridgeBio reported data showing its oral FGFR3 inhibitor infigratinib achieved height outcomes comparable to Voxzogo in achondroplasia, positioning an oral therapy as an alternative to existing...
FDA Setback on Disc: Questions Grow About Accelerated Approval Vouchers
BioCentury reports the FDA issued a complete response letter (CRL) to Disc, reinforcing a pattern of regulators rejecting biomarker-based approvals and raising doubts about the accelerated...
Anterior Raises $40M: AI to Speed Care Approvals from Weeks to Minutes
Anterior raised $40 million to expand its AI platform that automates administrative clinical work for health plans, aiming to reduce prior-authorization and utilization review timelines from weeks...
Droplet digital PCR... Absolute quantification without standard curves
Bio-Rad’s digital PCR technology eliminates dependence on standard curves by partitioning samples into thousands of droplets and using Poisson statistics to count target molecules directly,...
GaAs detector boosts 100 keV cryo‑EM — higher-resolution imaging for biology
Researchers unveiled a hybrid-pixel gallium arsenide (GaAs) counting detector optimized for 100 keV electron beams that improves imaging performance for cryo-electron microscopy (cryo-EM). The new...
Drinkable foam delivers gene therapy: New oral route targets esophageal cancer
Researchers led by Stephan, Cummings, and Fitzgerald reported a novel orally administered foam that delivers gene therapy locally to constrictive esophageal carcinoma, enabling targeted...
Cells’ own packages repurposed: Extracellular vesicles for safer gene delivery
Researchers outlined strategies to harness extracellular vesicles (EVs) as nonviral carriers for gene and protein delivery, positioning EVs as an alternative to traditional viral vectors that can...
GLP‑1 activates KATP channels—pericyte mechanism shields heart
A Nature Communications study found glucagon‑like peptide‑1 (GLP‑1) activates ATP-sensitive potassium (KATP) channels in coronary pericytes, revealing a previously unrecognized cardioprotective...
Ferroptosis nanotherapy reverses CAFs: Remodels colorectal tumor stroma
Researchers led by Wang and colleagues reported a ferroptosis-based nanotherapy that selectively targets colorectal cancer–associated fibroblasts (CAFs), reprogramming the tumor microenvironment...
Exact Sciences Posts Strong Quarter – Shareholders Set to Vote on $23B Abbott Deal
Exact Sciences reported a 23% year-over-year revenue increase in Q4 2025 and is moving toward shareholder approval of Abbott Laboratories’ proposed $23 billion acquisition. The company posted...
FDA Rejects Disc’s Rare-Disease Drug: Voucher Program Faces First Test
The FDA rejected Disc Medicine’s bitopertin for a rare blood disorder, citing uncertainties about whether the trial biomarker correlates with clinical benefit, according to STAT. Bitopertin was...
BridgeBio’s Oral Infigratinib Matches Voxzogo on Height – Adds Patient‑Friendly Option
BridgeBio reported data showing its FGFR3 inhibitor infigratinib produced height gains comparable to Voxzogo (vosoritide) in patients with achondroplasia while offering an oral dosing option,...
Vertex Sees Casgevy Uptick – Gene‑Edited Therapy Bolsters Results
Vertex reported a rebound in sales for Casgevy, the gene‑edited therapy developed with CRISPR Therapeutics, with quarterly sales more than tripling versus the prior quarter. Management cited the...